2023-10-26 08:00:00

Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Tr

Logo Benzinga
Benzinga
By Business Wire

XB002, a next-generation tissue factor-targeting antibody-drug conjugate, was well-tolerated at multiple dose levels

Pharmacokinetic analysis confirmed XB002 was stable with low levels of free payload

Exelixis, Inc. EXEL today announced promising initial results from the ongoing dose-escalation stage of JEWEL-101, a phase 1 study evaluating XB002, Exelixis' next-generation tissue factor-targeting antibody-drug conjugate. The data are being presented on Friday, October 28 during the Antibody-drug Conjugates Poster Session (abstract 256) at 10:00 a.m. CEST at the 34th Symposium on Molecular Targets and Cancer Therapeutics hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR).

AD
AD

Following promising preclinical data, it is encouraging to see that XB002 was well-tolerated across multiple dose levels with a pharmacokinetic analysis supporting the ability of XB002 to remain stable after infusion and reach its target before releasing its cytotoxic payload, said Susanna Ulahannan, M.D., M.Med., Assistant Professor of Medicine in the Section of Hematology/Oncology, University of Oklahoma College of Medicine and Associate Director of Oklahoma TSET Phase 1 Program, OU Health Stephenson Cancer Center at the OU Health Sciences Center. As the dose-escalation phase progresses, and we initiate enrollment into tumor specific cohorts, I look forward to learning more about how XB002 may benefit people with advanced solid tumors, in particular in tumor types with high unmet need.

Continue read on benzinga.com

AD
Logo Benzinga
Business / FinanceBy Globe Newswire2023-10-26 08:00:00
- MCLA-129 observed to be well tolerated with a favorable safety profile - Antitumor activity was observed among heavily pretreated patients, across multiple...

Logo NewsFileCorp
Press Release2023-09-29 18:06:00
Edmonton, Alberta--(Newsfile Corp. - September 29, 2023) - Pacylex Pharmaceuticals has dosed 16 patients in the early phase clinical trials of the company's...

Logo Benzinga
Business / FinanceBy Business Wire2023-10-11 13:07:00
Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-10-20 07:00:00
STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3 STORM's first-in-class lead program to enter clinical development in solid...

Logo PR Newswire
Research highlights value of IMTAC™ platform to identify drug targets for cancer treatments SAN JOSE, Calif., Oct. 7, 2022 /PRNewswire/ -- BridGene...

Logo Nasdaq
Business / FinanceBy Rtt News2023-10-04 12:25:03
(RTTNews) - Exelixis, Inc. (EXEL) announced the expansion of clinical trial collaboration and supply agreement with Bristol-Myers Squibb (BMY) to include the...

Logo Nasdaq
MarketsBy Zacks2023-10-05 14:15:00
Exelixis EXEL, an oncology-focused company, maintains momentum on the back of the solid performance of its lead drug Cabometyx amid stiff competition...

Logo Benzinga
Business / FinanceBy Business Wire2023-09-29 13:01:00
MAIA Biotechnology, Inc., (NYSE American: MAIA ) (MAIA, the Company), a targeted therapy, immuno-oncology company focused on developing potential...

Logo Benzinga
Business / FinanceBy Business Wire2023-10-26 08:00:00
-- STX-721 demonstrates potential best-in-class selectivity and strong anti-tumor activity across multiple EGFR and HER exon 20 mutant CDX and PDX models --...

Logo NewsFileCorp
Press Release2023-10-17 12:00:00
Salt Lake City, Utah--(Newsfile Corp. - October 17, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results...

Logo Benzinga
Business / FinanceBy Business Wire2023-10-17 07:45:00
Updated LuMIERE Phase 1 data demonstrated a manageable safety profile with some preliminary evidence of anti-tumor activity Eleven patients treated to date...

Logo Benzinga
Business / FinanceBy Business Wire2023-10-14 09:15:00
Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, today announced that dosing has begun in a Phase I clinical study to...

Logo Benzinga
MarketsBy Lara Goldstein2023-10-05 11:00:34
Clinical-stage biopharma company atai Life Sciences N.V. ATAI has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its...

Logo Benzinga
MarketsBy Lara Goldstein2023-10-05 11:00:34
Clinical-stage biopharma company atai Life Sciences N.V. ATAI has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its...

Logo PR Newswire
TechnologyPress Release2023-10-18 07:00:00
Synaffix obtains exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology CliCr® further expands the repertoire of...

Logo Benzinga
Business / FinanceBy Globe Newswire2023-10-10 11:36:02
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients...

Logo Benzinga
Business / FinanceBy Business Wire2023-10-12 07:01:00
- Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across four dose cohorts in the nine treated patients in the dose escalation...

Logo Nasdaq
Business / FinanceBy Rtt News2023-10-11 11:58:27
(RTTNews) - DICE Therapeutics, Inc. (DICE), a biopharmaceutical company, announced Tuesday positive topline data from its Phase 1 clinical trial of DC-806...

Logo EIN Presswire
SAINT LOUIS, MISSOURI, USA, October 25, 2023 / EINPresswire.com / -- Immunophotonics, Inc. announced today that Wei Chen, Ph.D., co-founder and director of...

Logo Nasdaq
Business / FinanceBy Rtt News2023-09-28 13:03:20
(RTTNews) - Florida-based KemPharm Inc. (KMPH) has announced positive top-line data from an exploratory phase I trial evaluating the cardiovascular safety of...